Sign In
Buy TLSA
$1.18
-0.180 (-13.24%)
At Close: Jun 03, 2026
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York
07:00am, Thursday, 28'th May 2026
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-C
Tiziana Life Sciences to present clinical updates at Jefferies healthcare conference
06:07am, Thursday, 28'th May 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026. CEO Ivor Elrifi and...
FedEx sum-of-the-parts valuation points to upside as freight spin-off approaches, UBS says
06:32am, Monday, 25'th May 2026
UBS is sticking with a Buy rating on FedEx Corp (NYSE:FDX, XETRA:FDX) and a price target of $445, as the company gets ready to spin off its freight business...
Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMI
05:06pm, Friday, 22'nd May 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has completed enrollment in its Phase 2 clinical trial evaluating foralumab for secondary progressive multiple sclerosis (SPMS), while also reporting expanded a
Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMI
12:48pm, Friday, 22'nd May 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has completed enrollment in its Phase 2 clinical trial evaluating foralumab for secondary progressive multiple...
Tiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trial
11:47am, Thursday, 21'st May 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has completed patient enrollment in its Phase 2a clinical trial evaluating intranasal foralumab in patients with non-active secondary progress
Dow Jones pokes ahead after IBM's quantum injection, Nvidia earnings
11:44am, Thursday, 21'st May 2026
3:40pm: Proactive news headlines Tiziana Life Sciences Ltd (NASDAQ:TLSA) completed patient enrollment in its Phase 2a clinical trial evaluating intranasal...
Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial
11:00am, Thursday, 21'st May 2026
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-C
Tiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trial
07:44am, Thursday, 21'st May 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has completed patient enrollment in its Phase 2a clinical trial evaluating intranasal foralumab in...
Tiziana Life Sciences price target boosted on foralumab update
03:17pm, Tuesday, 19'th May 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) saw Lucid Capital Markets raise its 12-month price target on the company to $9 from $8, while maintaining a “Buy” rating, following updated clinical data fo
MongoDB price target lifted by Bank of America ahead of earnings on execution confidence, Atlas momentum
11:35am, Tuesday, 19'th May 2026
MongoDB Inc (NASDAQ:MDB) saw Bank of America raise its price target on the database software company ahead of its upcoming first quarter earnings report,...
Tiziana Life Sciences price target boosted on foralumab update
11:12am, Tuesday, 19'th May 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) saw Lucid Capital Markets raise its 12-month price target on the company to $9 from $8, while maintaining a “Buy”...
Tiziana Life Sciences reports encouraging one-year data for intranasal foralumab in progressive MS
09:44am, Tuesday, 19'th May 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday that updated data from its Expanded Access Program showed intranasal foralumab continued to be well tolerated over extended treatment in patient
Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis
07:00am, Tuesday, 19'th May 2026
Favourable trends seen in stability of disability and clinically meaningful improvements in fatigue. BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd.
Tiziana Life Sciences reports encouraging one-year data for intranasal foralumab in progressive MS
05:42am, Tuesday, 19'th May 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday that updated data from its Expanded Access Program showed intranasal foralumab continued to be well...
